株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の研究開発におけるイムノアッセイ市場:2023年までの予測

Global Immunoassays in R&D Market Research Report Forecast to 2023

発行 Market Research Future 商品コード 909754
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
世界の研究開発におけるイムノアッセイ市場:2023年までの予測 Global Immunoassays in R&D Market Research Report Forecast to 2023
出版日: 2019年07月31日 ページ情報: 英文 188 Pages
概要

世界の研究開発におけるイムノアッセイ市場は、2023年までの間に8.18%のCAGRで成長すると予測されています。

当レポートは世界の研究開発におけるイムノアッセイ市場について調査しており、市場機会、成長および阻害要因、製品およびサービス・タイプ・用途・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 レポートプロローグ

第2章 市場の紹介

  • 定義
  • 調査範囲
  • 仮定のリスト
  • 市場構造

第3章 調査方法

  • 調査方法
  • 一次調査
  • 二次調査
  • 市場規模の推計
  • 予測モデル

第4章 市場力学

  • 概要
  • 成長要因
  • 阻害要因
  • 市場機会
  • 課題

第5章 市場要因分析

  • バリューチェーン分析
    • 研究開発および製品開発
    • 製造業
    • 流通・販売
    • 販売後の監視
  • ポーターのファイブフォース分析
  • 投資機会分析
  • 価格分析
  • 主な動向
  • 主な製薬組織
  • 主な研究所

第6章 世界市場:製品およびサービス別

  • 概要
  • キットおよび試薬
  • アナライザー
  • ソフトウェアおよびサービス

第7章 世界市場:タイプ別

  • 概要
  • 酵素免疫測定法(ELISA)
  • Enzyme-Linked Immunospot Assay(ELISpot)
  • ラジオイムノアッセイ(RIA)
  • 化学発光(CLIA)
  • 蛍光免疫測定法
  • その他

第8章 世界市場:用途別

  • 概要
  • 感染症
  • 癌研究
  • 内分泌学
  • 自己免疫疾患
  • その他

第9章 世界市場:エンドユーザー別

  • 概要
  • 製薬・バイオテクノロジー企業
  • 学術機関・研究所
  • その他

第10章 世界市場:地域別

  • 概要
  • 南北アメリカ
    • 北米
    • ラテンアメリカ
  • 欧州
    • 西欧
    • 北欧諸国
    • 東欧
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • 中東・アフリカ地域
    • 中東
    • アフリカ

第11章 競合情勢

  • 概要
  • 企業シェア分析

第12章 企業プロファイル

  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers
  • Becton, Dickinson and Company
  • Danaher Corporation
  • bioMerieux Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • Abcam plc

章13:付録

  • 議論の展望
図表

List of Tables

  • TABLE 1 MARKET SYNOPSIS
  • TABLE 2 LIST OF ASSUMPTIONS
  • TABLE 3 TOP COMPANIES (GLOBAL)
  • TABLE 4 TOP AMERICAS COMPANIES
  • TABLE 5 TOP EUROPE COMPANIES
  • TABLE 6 TOP ASIA-PACIFIC COMPANIES
  • TABLE 7 TOP MIDDLE EAST & AFRICA COMPANIES
  • TABLE 8 TOP RESEARCH INSTITUTES IN THE AMERICAS
  • TABLE 9 TOP RESEARCH INSTITUTES IN EUROPE
  • TABLE 10 TOP RESEARCH INSTITUTES IN ASIA-PACIFIC
  • TABLE 11 TOP RESEARCH INSTITUTES IN MIDDLE EAST & AFRICA
  • TABLE 12 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 13 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR KITS AND REAGENTS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 14 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ANALYZERS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 15 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 16 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 17 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ELISA, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 18 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ELISPOT, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 19 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR RIA, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 20 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR CLIA, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 21 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR FLUOROIMMUNOASSAY, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 22 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 23 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR INFECTIOUS DISEASES, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 24 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR CANCER RESEARCH, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 25 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ENDOCRINOLOGY, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 26 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 27 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 28 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 29 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 30 GLOBAL IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 31 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 32 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 33 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 34 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 35 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 36 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 37 AMERICAS: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 38 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 39 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 40 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 41 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 42 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 43 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 44 US: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 45 US: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 46 US: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 47 US: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 48 US: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 49 CANADA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 50 CANADA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 51 CANADA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 52 CANADA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 53 CANADA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 54 LATIN AMERICA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 55 LATIN AMERICA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 56 LATIN AMERICA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 57 LATIN AMERICA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 58 LATIN AMERICA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 59 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 60 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 61 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 62 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 63 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 64 EUROPE: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 65 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 66 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 67 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 68 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 69 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 70 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 71 GERMANY: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 72 GERMANY: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 73 GERMANY: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 74 GERMANY: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 75 GERMANY: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 76 FRANCE: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 77 FRANCE: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 78 FRANCE: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 79 FRANCE: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 80 FRANCE: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 81 UK: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 82 UK: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 83 UK: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 84 UK: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 85 UK: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 86 ITALY: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 87 ITALY: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 88 ITALY: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 89 ITALY: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 90 ITALY: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 91 SPAIN: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 92 SPAIN: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 93 SPAIN: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 94 SPAIN: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 95 SPAIN: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 96 SWITZERLAND: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 97 SWITZERLAND: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 98 SWITZERLAND: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 99 SWITZERLAND: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 100 SWITZERLAND: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 101 REST OF WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 102 REST OF WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 103 REST OF WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 104 REST OF WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 105 REST OF WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 106 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 107 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 108 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 109 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 110 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 111 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 112 NORWAY: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 113 NORWAY: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 114 NORWAY: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 115 NORWAY: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 116 NORWAY: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 117 SWEDEN: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 118 SWEDEN: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 119 SWEDEN: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 120 SWEDEN: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 121 SWEDEN: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 122 DENMARK: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 123 DENMARK: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 124 DENMARK: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 125 DENMARK: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 126 DENMARK: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 127 REST OF NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 128 REST OF NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 129 REST OF NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 130 REST OF NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 131 REST OF NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 132 EASTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 133 EASTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 134 EASTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 135 EASTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 136 EASTERN EUROPE: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 137 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 138 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 139 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 140 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 141 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 142 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 143 JAPAN: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 144 JAPAN: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 145 JAPAN: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 146 JAPAN: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 147 JAPAN: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 148 CHINA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 149 CHINA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 150 CHINA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 151 CHINA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 152 CHINA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 153 INDIA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 154 INDIA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 155 INDIA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 156 INDIA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 157 INDIA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 158 AUSTRALIA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 159 AUSTRALIA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 160 AUSTRALIA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 161 AUSTRALIA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 162 AUSTRALIA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 163 SOUTH KOREA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 164 SOUTH KOREA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 165 SOUTH KOREA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 166 SOUTH KOREA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 167 SOUTH KOREA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 168 REST OF ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 169 REST OF ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 170 REST OF ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 171 REST OF ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 172 REST OF ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 174 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 175 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 176 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 177 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 178 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 179 MIDDLE EAST: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 180 MIDDLE EAST: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 181 MIDDLE EAST: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 182 MIDDLE EAST: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 183 MIDDLE EAST: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 184 AFRICA: IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2015-2023 (USD MILLION)
  • TABLE 185 AFRICA: IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 186 AFRICA: IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 187 AFRICA: IMMUNOASSAYS IN R&D MARKET, BY END USER, 2015-2023 (USD MILLION)
  • TABLE 188 AFRICA: IMMUNOASSAYS IN R&D MARKET FOR ACADEMIC INSTITUTIONS AND LABORATORIES, BY TYPE, 2015-2023 (USD MILLION)

List of Figures

  • FIGURE 1 GLOBAL IMMUNOASSAY IN R&D MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS OF MRFR
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES
  • FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE IMMUNOASSAYS IN R&D MARKET
  • FIGURE 5 VALUE CHAIN ANALYSIS: GLOBAL IMMUNOASSAYS IN R&D MARKET
  • FIGURE 6 PORTER'S FIVE FORCE ANALYSIS: GLOBAL IMMUNOASSAYS IN R&D MARKET
  • FIGURE 7 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY PRODUCT & SERVICE, 2017 AND 2023 (USD MILLION)
  • FIGURE 8 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY TYPE, 2017 AND 2023 (USD MILLION)
  • FIGURE 9 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY APPLICATION, 2017 AND 2023 (USD MILLION)
  • FIGURE 10 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY END USER, 2017 AND 2023 (USD MILLION)
  • FIGURE 11 GLOBAL IMMUNOASSAYS IN R&D MARKET, BY REGION, 2017 AND 2023 (USD MILLION)
  • FIGURE 12 AMERICAS: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2017 (%)
  • FIGURE 13 NORTH AMERICA: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2017 (%)
  • FIGURE 14 EUROPE: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2017 (%)
  • FIGURE 15 WESTERN EUROPE: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2017 (%)
  • FIGURE 16 NORDIC COUNTRIES: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2017 (%)
  • FIGURE 17 ASIA-PACIFIC: IMMUNOASSAYS IN R&D MARKET, BY COUNTRY, 2017 (%)
  • FIGURE 18 MIDDLE EAST & AFRICA: IMMUNOASSAYS IN R&D MARKET, BY REGION, 2017 (%)
  • FIGURE 19 GLOBAL IMMUNOASSAY IN R&D MARKET SHARE ANALYSIS, 2017 (%)
目次

Global Immunoassay in R&D Market: Information by Product & Service (Kits and Reagents, Analyzers and Software and Services), Type (Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay and others), Application (Infectious Diseases, Cancer Research, Endocrinology, Autoimmune Diseases and others), End User (Pharmaceutical and Biotechnology Companies, Academic Institutions and Laboratories and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2023

Market analysis

The rising occurrence percentage of chronic and communicable illnesses, augmented research & development investment (R&D) and technical developments thrusting the market growth. Though, the risen price of immunoassay processes and the heavy cost of immunoassay systems compel the development of the market, the occurrence in the incidence rates of diseases such as kidney problems, thyroid problems, adrenal gland tumors and heart disorders is projected to determine the progress of the market. For example, according to the data published by the Centers for Disease Control and Prevention in 2017, the American Heart Association stated in 2015 that every year, about 7,35,000 Americans grieve from heart attacks. Furthermore, the enlarged funds by various government and non-governmental establishments in research has powered the evolution of the market. In addition, technological advancements in immunoassay testing are possibly here to support market growth. In contrast, the heavy price of immunoassay events and the high value of immunoassay systems is predicted to hinder the market growth. The Global Immunoassay in R&D Market is projected to record a CAGR of 8.18% and is estimated to reach USD 7,716.6 million by 2023. Immunoassays are in-vitro exams that use antigen-antibody reaction to perceive the meditations of a wide range of biological constituents in the blood and other fluids. Immunoassays are widely used in several zones of therapeutic research such as beneficial drug monitoring, disease analysis, medical pharmacokinetic, and bioequivalence trainings in drug discovery, etc.

Market segmentation

The global immunoassay in the R&D market has been segmented into type, application, and end user. By type, the market has been categorized as Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunoprotect Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay, and others. Based on application, the market has been divided into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. By end-user, the market has been segregated into pharmaceutical and biotechnology companies, academic institutions and laboratories, and others. The pharmaceutical and biotechnology companies segment settled for a market value of USD 1,742.6 million in 2017. In November 2018, bioMerieux announced the acquisition of a majority shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd (China). With this acquisition, the company strengthened its presence in China and therefore, in the global immunoassay in the R&D. In March 2018, Hoffmann-La Roche Ltd tossed its initial wholly automatic Zika IgG immunoassay to help detect the Zika virus. The authorized name of this diagnostic test is Elecsys Zika IgG immunoassay. It is accessible in all countries, which entail a CE mark. In October 2017, Abbott declared the US Food & Drug Administration (FDA) authorization for its Alinity CI-Series instruments for clinical chemistry and immunoassay diagnostics. The Global Immunoassay in R&D Market is segmented by Type (Enzyme-Linked Immunospot Assay (ELISpot), Chemiluminescence (CLIA), Fluoroimmunoassay, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA) and others), by Application ( Endocrinology, Autoimmune Diseases, Cancer Research, Infectious Diseases and Others, By End User (Academic Institutions and Laboratories, Pharmaceutical and Biotechnology Companies and others) and lastly it is given by Region and is further provided below in its regional analysis.

Regional analysis

Geographically, the Immunoassay in R&D market are split in regions like Americas, Europe, Asia-Pacific and MEA. In Americas, the regions focused are: North America, US, Canada and Latin America followed by Western Europe, Germany, UK Spain, France, Italy, Eastern Europe and the Rest of Western Europe in the European region, while Asia-Pacific comprises of regions like South Korea, India, Australia, China, Japan and the rest of Asia Pacific respectively. The MEA comprises the regions Middle East and Africa.

Major players

The projected onlookers in the Immunoassay in R&D market are Hospitals and clinics, Medical device manufacturers and distributors, Pharmaceutical companies, Government research organizations and Regulatory agencies. Also, the vital players in the Immunoassay in R&D market are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Abcam PLC (United Kingdom), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Siemens Healthineers (Germany), Danaher Corporation (US), bioMerieux Inc. (France), Abbott Laboratories (US) and Sysmex Corporation (Japan). Additional companies which can be customized into the final report are Monobind Inc., Mindray Boditech Med, Inc., Ortho Clinical Diagnostics and Diasorin SpA.

Table of Contents

1 Report Prologue

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 List of Assumptions
  • 2.4 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Drivers
    • 4.2.1 Increasing incidence rate of chronic and infectious diseases
    • 4.2.2 Increased R&D investments by public and private organizations
    • 4.2.3 Technological advancements in immunoassay testing
  • 4.3 Restraints
    • 4.3.1 High cost of immunoassay procedures
    • 4.3.2 High price of immunoassay systems
  • 4.4 Opportunity
    • 4.4.1 Integration of the microfluidics technology in immunoassays
  • 4.5 Challenge
    • 4.5.1 Technical difficulties during testing

5 Market Factor Analysis

  • 5.1 Value Chain Analysis
    • 5.1.1 R&D and Product Development
    • 5.1.2 Manufacturing
    • 5.1.3 Distribution & Sales
    • 5.1.4 Post-Sales Monitoring

  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Buyers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitutes
    • 5.2.5 Intensity of Rivalry
  • 5.3 Investment Opportunity Analysis
  • 5.4 Pricing Analysis
  • 5.5 Major Trends
    • 5.5.1 Growing demand for automated immunoassay systems
    • 5.5.2 Development of highly sensitive immunoassay equipment
    • 5.5.3 Technology Trends
  • 5.6 Major Pharmaceutical Organizations (by R&D Revenues)
  • 5.7 Top Research Institutes

6 Global Immunoassays in R&D Market, by Product & Service

  • 6.1 Overview
  • 6.2 Kits and Reagents
  • 6.3 Analyzers
  • 6.4 Software and Services

7 Global Immunoassays in R&D Market, by Type

  • 7.1 Overview
  • 7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
  • 7.3 Enzyme-Linked Immunospot Assay (ELISpot)
  • 7.4 RadioImmunoassay (RIA)
  • 7.5 Chemiluminescence (CLIA)
  • 7.6 Fluoroimmunoassay
  • 7.7 Others

8 Global Immunoassays in R&D Market, by Application

  • 8.1 Overview
  • 8.2 Infectious Diseases
  • 8.3 Cancer Research
  • 8.4 Endocrinology
  • 8.5 Autoimmune Diseases
  • 8.6 Others

9 Global Immunoassays in R&D Market, by End User

  • 9.1 Overview
  • 9.2 Pharmaceutical and Biotechnology Companies
  • 9.3 Academic Institutions and Laboratories
  • 9.4 Others

10 Global Immunoassays in R&D Market, by Region

  • 10.1 Overview
  • 10.2 Americas
    • 10.2.1 North America
      • 10.2.1.1 US
      • 10.2.1.2 Canada
    • 10.2.2 Latin America
  • 10.3 Europe
    • 10.3.1 Western Europe
      • 10.3.1.1 Germany
      • 10.3.1.2 France
      • 10.3.1.3 UK
      • 10.3.1.4 Italy
      • 10.3.1.5 Spain
      • 10.3.1.6 Switzerland
      • 10.3.1.7 Rest of Western Europe
    • 10.3.2 Nordic Countries
      • 10.3.2.1 Norway
      • 10.3.2.2 Sweden
      • 10.3.2.3 Denmark
      • 10.3.2.4 Rest of Nordic Countries
    • 10.3.3 Eastern Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia-Pacific
  • 10.5 Middle East & Africa
    • 10.5.1 Middle East
    • 10.5.2 Africa

11 Company Landscape

  • 11.1 Overview
  • 11.2 Company Share Analysis

12 Company Profiles

  • 12.1 Bio-Rad Laboratories, Inc.
    • 12.1.1 Company Overview
    • 12.1.2 Financial Overview
    • 12.1.3 Products/Services Offered
    • 12.1.4 Key Developments
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Strategies
  • 12.2 Thermo Fisher Scientific Inc.
    • 12.2.1 Company Overview
    • 12.2.2 Financial Overview
    • 12.2.3 Products/Services Offered
    • 12.2.4 Key Developments
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Strategies
  • 12.3 Siemens Healthineers
    • 12.3.1 Company Overview
    • 12.3.2 Financial Overview
    • 12.3.3 Products/Services Offered
    • 12.3.4 Key Developments
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Strategies
  • 12.4 Becton, Dickinson and Company
    • 12.4.1 Company Overview
    • 12.4.2 Financial Overview
    • 12.4.3 Products/Services Offered
    • 12.4.4 Key Developments
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Strategies
  • 12.5 Danaher Corporation
    • 12.5.1 Company Overview
    • 12.5.2 Financial Overview
    • 12.5.3 Products/Services Offered
    • 12.5.4 Key Developments
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Strategies
  • 12.6 bioMerieux Inc.
    • 12.6.1 Company Overview
    • 12.6.2 Financial Overview
    • 12.6.3 Products/Services Offered
    • 12.6.4 Key Developments
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Strategies
  • 12.7 Abbott Laboratories
    • 12.7.1 Company Overview
    • 12.7.2 Financial Overview
    • 12.7.3 Products/Services Offered
    • 12.7.4 Key Developments
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Strategies
  • 12.8 F. Hoffmann-La Roche Ltd
    • 12.8.1 Company Overview
    • 12.8.2 Financial Overview
    • 12.8.3 Products/Services Offered
    • 12.8.4 Key Developments
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Strategies
  • 12.9 Sysmex Corporation
    • 12.9.1 Company Overview
    • 12.9.2 Financial Overview
    • 12.9.3 Products/Services Offered
    • 12.9.4 Key Developments
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Strategies
  • 12.1 Abcam plc
    • 12.10.1 Company Overview
    • 12.10.2 Financial Overview
    • 12.10.3 Products/Services Offered
    • 12.10.4 Key Developments
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Strategies

13 Appendix

  • 13.1 Discussion Blue Print
Back to Top